Acalabrutinib D4 (ACP196 D4) is the tetra-deuterated form of Acalabrutinib (ACP-196; trade name: Calquence), which is a selective and second-generation BTK inhibitor approved in 2017 by FDA to treat adults with mantle cell lymphoma.

纯度：≥98%

CAS：1420477-60-6 (unlabeled)